JP2017521064A - ピーナッツアレルギーの治療のための核酸 - Google Patents

ピーナッツアレルギーの治療のための核酸 Download PDF

Info

Publication number
JP2017521064A
JP2017521064A JP2016575347A JP2016575347A JP2017521064A JP 2017521064 A JP2017521064 A JP 2017521064A JP 2016575347 A JP2016575347 A JP 2016575347A JP 2016575347 A JP2016575347 A JP 2016575347A JP 2017521064 A JP2017521064 A JP 2017521064A
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
acid molecule
lamp
peanut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521064A5 (enExample
Inventor
ウィリアム ハール，
ウィリアム ハール，
テリー ハイラント，
テリー ハイラント，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomic Therapeutics Inc
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Publication of JP2017521064A publication Critical patent/JP2017521064A/ja
Publication of JP2017521064A5 publication Critical patent/JP2017521064A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016575347A 2014-06-23 2015-06-23 ピーナッツアレルギーの治療のための核酸 Pending JP2017521064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015981P 2014-06-23 2014-06-23
US62/015,981 2014-06-23
PCT/US2015/037240 WO2015200357A2 (en) 2014-06-23 2015-06-23 Nucleic acids for treatment of peanut allergies

Publications (2)

Publication Number Publication Date
JP2017521064A true JP2017521064A (ja) 2017-08-03
JP2017521064A5 JP2017521064A5 (enExample) 2018-07-26

Family

ID=53546722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575347A Pending JP2017521064A (ja) 2014-06-23 2015-06-23 ピーナッツアレルギーの治療のための核酸

Country Status (9)

Country Link
US (2) US20170304432A1 (enExample)
EP (1) EP3157558A2 (enExample)
JP (1) JP2017521064A (enExample)
KR (1) KR20170019457A (enExample)
CN (1) CN106459994A (enExample)
AU (2) AU2015280143A1 (enExample)
BR (1) BR112016030439A2 (enExample)
CA (1) CA2952726A1 (enExample)
WO (1) WO2015200357A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210142000A (ko) * 2019-03-13 2021-11-23 소마젠 인크 알레르기 치료를 위한 에피토프-기반 접근법 및 크론병에 대한 억제제

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
WO2017186808A1 (en) * 2016-04-27 2017-11-02 Allergy Therapeutics (Uk) Limited Treatment of peanut allergy
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
WO2018195527A1 (en) * 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
US11382934B2 (en) 2017-07-18 2022-07-12 Before Brands, Inc. Methods for making mixed allergen compositions
CA3099495A1 (en) 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating mite allergy
WO2019216396A1 (ja) 2018-05-11 2019-11-14 アステラス製薬株式会社 甲殻類アレルギー治療のための核酸
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
CN109115737B (zh) * 2018-07-27 2021-03-26 青岛大学 一种三螺旋pH生物传感器及其应用
CA3127337A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
CN112225815A (zh) * 2020-09-30 2021-01-15 四川携光生物技术有限公司 一种牛奶、小麦、花生及大豆过敏原融合蛋白及其构建方法、应用
CN114438088B (zh) * 2020-11-03 2025-05-23 韩达 一种溶酶体靶向的核酸嵌合体的制备及应用
KR102527331B1 (ko) * 2020-11-10 2023-05-02 (주)프로테옴텍 밀가루 유래의 오메가-5-글리아딘의 신규 에피토프 중합체 및 이의 용도
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof
CN115057927B (zh) * 2022-05-30 2024-02-20 南开大学 一种花生过敏原Ara h1特异性纳米抗体及其应用
WO2025199077A1 (en) * 2024-03-19 2025-09-25 Modernatx, Inc. Tolerizing antigen specific immunotherapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019978A1 (en) * 2002-08-29 2004-03-11 National University Of Singapore Recombinant nucleic acid useful for inducing protective immune response against allergens
WO2013187906A1 (en) * 2012-06-15 2013-12-19 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018185A1 (en) * 1992-03-03 1993-09-16 The Salk Institute For Biological Studies Receptor internalization signals
US9774230B2 (en) * 2015-11-25 2017-09-26 Caterpillar Inc. Generator set having coupling member between flywheel and generator

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019978A1 (en) * 2002-08-29 2004-03-11 National University Of Singapore Recombinant nucleic acid useful for inducing protective immune response against allergens
WO2013187906A1 (en) * 2012-06-15 2013-12-19 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOPPELMAN S. J. ET AL., 'RELEVANCE OF ARA H1, ARA H2 AND ARA H3 IN PEANUT-ALLERGIC PATIENTS, AS DETE, JPN6019014047, ISSN: 0004020009 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210142000A (ko) * 2019-03-13 2021-11-23 소마젠 인크 알레르기 치료를 위한 에피토프-기반 접근법 및 크론병에 대한 억제제
JP2022524757A (ja) * 2019-03-13 2022-05-10 プソマーゲン， インコーポレイテッド アレルギー治療のためのエピトープベースアプローチ及びクローン病のための阻害薬
JP7266700B2 (ja) 2019-03-13 2023-04-28 プソマーゲン， インコーポレイテッド アレルギー治療のためのエピトープベースアプローチ及びクローン病のための阻害薬
KR102811748B1 (ko) * 2019-03-13 2025-05-26 주식회사 마크로젠 알레르기 치료를 위한 에피토프-기반 접근법 및 크론병에 대한 억제제

Also Published As

Publication number Publication date
EP3157558A2 (en) 2017-04-26
AU2020204277A1 (en) 2020-07-16
BR112016030439A2 (pt) 2018-07-17
US20190298821A1 (en) 2019-10-03
AU2015280143A1 (en) 2017-01-05
WO2015200357A3 (en) 2016-04-21
KR20170019457A (ko) 2017-02-21
US20170304432A1 (en) 2017-10-26
CN106459994A (zh) 2017-02-22
CA2952726A1 (en) 2015-12-30
WO2015200357A2 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
US20190298821A1 (en) Nucleic Acids for Treatment of Peanut Allergies
EP2861240B1 (en) Nucleic acids for treatment of allergies
JP5998370B2 (ja) Ｅｇｆｒｖｉｉｉに対する免疫応答を誘発する方法および組成物
ES2752141T3 (es) Vacuna de ADN para uso en pacientes con cáncer de páncreas
JP2014518620A (ja) リポソーム製剤
CA3044074A1 (en) Nucleic acids for treatment of allergies
CA2377530A1 (en) Compositions and methods for the treatment or prevention of autoimmune disorders
US10507234B2 (en) Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with Fc-coupled antigens
Husseiny et al. Factors affecting Salmonella-based combination immunotherapy for prevention of type 1 diabetes in non-obese diabetic mice
TW201710285A (zh) 表皮生長因子受體變體ｉｉｉ－間皮素融合物及使用其之方法
US9173928B2 (en) DNA vaccine for Alzheimer's disease
JP6353510B2 (ja) アレルギー治療のための核酸
EP2412811B1 (en) Dna vaccine for alzheimer's disease
JP6088584B2 (ja) アレルギー治療のための核酸
US10548962B2 (en) Use of the salmonella SPP type III secretion proteins as a protective vaccination
Alghonemy et al. Systemic immune response development in Albino rats after retrograde instillation of COVID-19 vaccine to submandibular salivary gland: An experimental study
KR102898622B1 (ko) Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US20210253646A1 (en) Vaccine vector encoding mutated gnaq for treatment of uveal melanoma and cancers having oncogenic mutations on gnaq and gna11 proteins
CN115135338A (zh) 包含具有二硫桥重排的人vegf-a突变体的多肽以及包含其的组合物
Pfrengle et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20170224

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20170224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190419

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191209